- The excitement from FDA approval of Biogen’s Alzheimer’s drug Aduhelm is subsiding.
- The FDA is being scrutinized about the approval, and key hospitals are not prescribing Aduhelm.
- The fall in Biogen share price reflects Aduhelm seen as not an effective treatment for Alzheimer’s; share price falls for Roche and Eli Lilly show pessimism about their Alzheimer's drugs.
- It is tough, but paying $56,000 annually in hope rather than reality seems to be where Aduhelm sits now.
- Investors interested in Biogen might consider Biogen’s portfolio without ascribing significant valuation to Aduhelm.
For further details see:
Biogen And Alzheimer's Drug: Hope Is Not Enough